David A. Siegel Humacyte, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Humacyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 44,600 shares of HUMA stock, worth $110,608. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,600
Previous 147,100
69.68%
Holding current value
$110,608
Previous $742,000
89.76%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding HUMA
# of Institutions
181Shares Held
59.9MCall Options Held
1.05MPut Options Held
877K-
Black Rock Inc. New York, NY7.14MShares$17.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.6MShares$16.4 Million0.0% of portfolio
-
State Street Corp Boston, MA4.27MShares$10.6 Million0.0% of portfolio
-
Heights Capital Management, Inc San Francisco, CA4.03MShares$9.98 Million3.22% of portfolio
-
Woodline Partners LP San Francisco, CA3.95MShares$9.8 Million0.05% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $255M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...